Vectus Biosystems logo

VBS - Vectus Biosystems Share Price

A$0.96 0.0  0.0%

Last Trade - 12/05/21

Micro Cap
Market Cap £16.7m
Enterprise Value £16.4m
Revenue £55.7k
Position in Universe 1321st / 1911
Unlock VBS Revenue
Relative Strength (%)
1m -14.0%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -38.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.78 0.075 0.049 0.002 0.000 0.051 -42.0%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, VectusBiosystems Ltd revenues increased from A$0K to A$50K. Netloss increased from A$1.1M to A$2.2M. Revenues reflectInterest and other income remaining flat at A$0K. Highernet loss reflects Research & Development Expense increasefrom A$234K to A$727K (expense), Interest Exp-Net ofCapitalized Interest increase from A$81K to A$480K(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


VBS Revenue Unlock VBS Revenue

Net Income

VBS Net Income Unlock VBS Revenue

Normalised EPS

VBS Normalised EPS Unlock VBS Revenue

PE Ratio Range

VBS PE Ratio Range Unlock VBS Revenue

Dividend Yield Range

VBS Dividend Yield Range Unlock VBS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
VBS EPS Forecasts Unlock VBS Revenue
Profile Summary

Vectus Biosystems Limited is engaged in medical Research and Development. The Company's drug candidates can be orally administered. The Company's primary lead compound, VB0004, has been shown to be both anti-hypertensive and anti-fibrotic in the heart and kidneys. Using its platform technology, the Company has constructed a library of more than 200 small molecules with varying degrees of anti-hypertensive and/or anti-fibrotic properties. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH), as well as pulmonary fibrotic diseases. Accugen is a platform, developed by the Company's subsidiary, Accugen Pty Limited. Accugen comprises reagents and software that quantitate quantitative polymerase chain reaction (qPCR) reactions, which measures the amount of Deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in a sample. It identifies drug targets with specific activity in the heart, kidneys, lungs and liver.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated December 12, 2005
Public Since February 23, 2016
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Australian Stock Exchange - SEATS
Shares in Issue 31,655,394
Free Float (0.0%)
Eligible for
VBS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for VBS
Upcoming Events for VBS
Frequently Asked Questions for Vectus Biosystems
What is the Vectus Biosystems share price?

As of 12/05/21, shares in Vectus Biosystems are trading at A$0.96, giving the company a market capitalisation of £16.7m. This share price information is delayed by 15 minutes.

How has the Vectus Biosystems share price performed this year?

Shares in Vectus Biosystems are currently trading at A$0.96 and the price has moved by 95.92% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Vectus Biosystems price has moved by 49.85% over the past year.

What are the analyst and broker recommendations for Vectus Biosystems?

There are no analysts currently covering Vectus Biosystems.

When will Vectus Biosystems next release its financial results?

Vectus Biosystems is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Vectus Biosystems dividend yield?

Vectus Biosystems does not currently pay a dividend.

Does Vectus Biosystems pay a dividend?

Vectus Biosystems does not currently pay a dividend.

When does Vectus Biosystems next pay dividends?

Vectus Biosystems does not currently pay a dividend.

How do I buy Vectus Biosystems shares?

To buy shares in Vectus Biosystems you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Vectus Biosystems?

Shares in Vectus Biosystems are currently trading at A$0.96, giving the company a market capitalisation of £16.7m.

Where are Vectus Biosystems shares listed? Where are Vectus Biosystems shares listed?

Here are the trading details for Vectus Biosystems:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: VBS
What kind of share is Vectus Biosystems?

Based on an overall assessment of its quality, value and momentum, Vectus Biosystems is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Vectus Biosystems share price forecast 2021?

We were not able to load any forecast data for Vectus Biosystems.

How can I tell whether the Vectus Biosystems share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vectus Biosystems. Over the past six months, the relative strength of its shares against the market has been -10.05%. At the current price of A$0.96, shares in Vectus Biosystems are trading at 8.05% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Vectus Biosystems PE Ratio?

We were not able to find PE ratio data for Vectus Biosystems.

Who are the key directors of Vectus Biosystems?

Vectus Biosystems's management team is headed by:

Karen Duggan - CEO
Maurie Stang - VCH
Peter Bush - NED
Ronald Shnier - NID
Robert Waring - SEC
Susan Pond - NED
Who are the major shareholders of Vectus Biosystems?

Here are the top five shareholders of Vectus Biosystems based on the size of their shareholding:

Ajjika Technology Pty. Ltd. Corporation
Percentage owned: 10.11% (3.20m shares)
Energy Trading Systems Pty. Ltd. Corporation
Percentage owned: 8.06% (2.55m shares)
Spinite Pty. Ltd. Corporation
Percentage owned: 4.87% (1.54m shares)
3rd Pulitano Pty. Ltd. Corporation
Percentage owned: 2.53% (802k shares)
Grizzly Holdings Pty. Ltd. Corporation
Percentage owned: 2.32% (733k shares)
Similar to VBS
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.